Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endometriosis: cost estimates and methodological perspective.

S Simoens1, L Hummelshoj, T D'Hooghe

  • 1Research Centre for Pharmaceutical Care and Pharmaco-Economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2, PO Box 521, Herestraat 49, 3000 Leuven, Belgium. steven.simoens@pharm.kuleuven.be

Human Reproduction Update
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Live birth in patients stimulated with r-hFSH or r-hFSH: r-hLH is strongly associated with cumulus cell derived gene expression models.

Reproductive biology and endocrinology : RB&E·2025
Same author

Cost-utility analysis of expanding the colorectal cancer screening policy in Flanders.

Public health·2024
Same author

Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective.

Best practice & research. Clinical obstetrics & gynaecology·2023
Same author

Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.

Best practice & research. Clinical obstetrics & gynaecology·2023
Same author

What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.

Human reproduction update·2023
Same author

The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis.

Human reproduction (Oxford, England)·2021
Same journal

Clinical outcomes and euploidy rates of embryos derived from zygotes with nonpronuclear (0PN) and monopronuclear (1PN) in IVF or ICSI cycles: a systematic review and meta-analysis.

Human reproduction update·2026
Same journal

Sperm mitochondrial DNA copy number: a marker of male fertility and reproductive success.

Human reproduction update·2026
Same journal

Embryo-derived extracellular vesicles and their potential as biomarkers for embryo quality during IVF: a systematic review.

Human reproduction update·2026
Same journal

Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Human reproduction update·2026
Same journal

Maternal genetic variants associated with aneuploid conception: a narrative review.

Human reproduction update·2026
Same journal

Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.

Human reproduction update·2026
See all related articles

Endometriosis costs the US $22 billion annually, with significant healthcare and productivity losses per patient. More research is needed to accurately assess treatment costs and the disease

Area of Science:

  • Reproductive health economics
  • Gynecological disorder research
  • Healthcare cost analysis

Background:

  • Endometriosis imposes substantial economic burdens.
  • Existing cost-of-illness studies vary in methodology and scope.
  • Accurate economic impact assessment is crucial for healthcare policy.

Purpose of the Study:

  • To systematically review estimates and methodologies of studies quantifying endometriosis costs.
  • To analyze direct (healthcare) and indirect (productivity loss) economic impacts.
  • To identify limitations in current cost estimation and suggest future research directions.

Main Methods:

  • Systematic review of cost-of-illness and cost analyses.
  • Inclusion of studies quantifying diagnostic and treatment costs.

Related Experiment Videos

  • Extrapolation of per-patient costs to the US population.

    • Main Results:

    • Annual healthcare costs: $2801 per patient.
    • Annual productivity loss costs: $1023 per patient.
    • Estimated total annual cost for the US: $22 billion (2002 data, 10% prevalence).
    • Costs exceed those of Crohn's disease and migraine.
    • Insufficient data on comparative medical vs. surgical treatment costs and costs in infertile patients.

    Conclusions:

    • Endometriosis represents a significant economic burden.
    • Current cost estimates are subject to bias due to methodological limitations.
    • Need for robust, longitudinal studies to accurately model the chronic nature and costs of endometriosis.